It’s time for oligonucleotide therapeutics to step into the light. With an increase in both the number of commercialized therapies and the diversity in the oligos themselves, therapeutic developers need to scale up quickly to meet demand while utilizing the same manufacturing suite for an assortment of oligo drugs. Considering manufacturability, scale-up, and the use different technologies with the end in mind will help deliver process efficiency. In this presentation, we’ll discuss strategies to future-proof your manufacturing by considering all the options for increasing the yield of the different oligo therapeutics you have in development.
